Maria Borbolla-La
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: July 15, 2026
Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.
Journal: Cancer immunology, immunotherapy : CII
Published: February 02, 2026
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: July 06, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 27, 2025
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.
Journal: Cancers
Published: July 25, 2023
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.
Journal: International journal of molecular sciences
Published: November 07, 2022
Is melanoma mortality declining in Spain? Analysis of trends from 1975 to 2016.
Journal: The British journal of dermatology
Published: May 15, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026